These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9390106)

  • 21. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
    Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS
    J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.
    Schrenk D; Brockmeier D; Mörike K; Bock KW; Eichelbaum M
    Eur J Clin Pharmacol; 1998 Jan; 53(5):361-7. PubMed ID: 9516038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
    Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis.
    Langmann P; Bienert A; Zilly M; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 May; 5(5):217-21. PubMed ID: 10806124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory tests for acute alcohol consumption: results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence.
    Helander A; Eriksson CJ;
    Alcohol Clin Exp Res; 2002 Jul; 26(7):1070-7. PubMed ID: 12170117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin.
    Härtter S; Korhonen T; Lundgren S; Rane A; Tolonen A; Turpeinen M; Laine K
    Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):300-4. PubMed ID: 17040215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Smoking reduction and temporary abstinence: new approaches for smoking cessation].
    Le Houezec J; Säwe U
    J Mal Vasc; 2003 Dec; 28(5):293-300. PubMed ID: 14978435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omeprazole weakly inhibits CYP1A2 activity in man.
    Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Smoking, alcohol and caffeine consumption of mothers before, during and after pregnancy--results of the study 'breast-feeding habits in Bavaria'].
    Rebhan B; Kohlhuber M; Schwegler U; Koletzko B; Fromme H
    Gesundheitswesen; 2009 Jul; 71(7):391-8. PubMed ID: 19326332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraxanthine/caffeine ratio: as an index for CYP1A2 activity in polycyclic aromatic hydrocarbons exposed subjects.
    Wittayalertpanya S; Hinsui Y; Lawanprasert S
    J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S310-7. PubMed ID: 12930004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.
    Perera V; Gross AS; Forrest A; Landersdorfer CB; Xu H; Ait-Oudhia S; McLachlan AJ
    Drug Metab Dispos; 2013 Nov; 41(11):1957-66. PubMed ID: 23996078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.
    Fontana RJ; deVries TM; Woolf TF; Knapp MJ; Brown AS; Kaminsky LS; Tang BK; Foster NL; Brown RR; Watkins PB
    Br J Clin Pharmacol; 1998 Sep; 46(3):221-8. PubMed ID: 9764962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics.
    Girre C; Lucas D; Hispard E; Menez C; Dally S; Menez JF
    Biochem Pharmacol; 1994 Apr; 47(9):1503-8. PubMed ID: 7910460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.
    Carrillo JA; Benitez J
    Br J Clin Pharmacol; 1996 Jun; 41(6):605-8. PubMed ID: 8799528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
    Plowchalk DR; Rowland Yeo K
    Eur J Clin Pharmacol; 2012 Jun; 68(6):951-60. PubMed ID: 22258279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobacco Smoke and CYP1A2 Activity in a US Population with Normal Liver Enzyme Levels.
    Garduno A; Wu T
    Int J Environ Res Public Health; 2021 Feb; 18(5):. PubMed ID: 33668222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A urinary metabolite ratio that reflects systemic caffeine clearance.
    Campbell ME; Spielberg SP; Kalow W
    Clin Pharmacol Ther; 1987 Aug; 42(2):157-65. PubMed ID: 3608349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.
    Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
    Eur J Clin Pharmacol; 2008 Apr; 64(4):381-5. PubMed ID: 18157525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS.
    Lajin B; Schweighofer N; Goessler W; Obermayer-Pietsch B
    Talanta; 2021 Nov; 234():122658. PubMed ID: 34364467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.